The United States Patent and Trademark Office (USPTO) has granted patent US12581252B2 to Relay Therapeutics, Inc. The patent, titled 'Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors,' covers novel compounds and pharmaceutical compositions thereof, as well as methods for inhibiting the activity of PI3Kα enzymes and treating disorders associated with PI3Kα signaling. The patent was filed on April 29, 2021, and granted on March 17, 2026, with 20 claims.

This patent grant represents a new intellectual property asset for Relay Therapeutics, potentially impacting their drug development pipeline for oncology or other therapeutic areas where PI3Kα signaling is implicated. While this is a patent grant and not a regulatory rule, it signifies a new innovation in the pharmaceutical space. Companies operating in similar therapeutic areas should be aware of this granted patent as it may affect their freedom to operate or potential licensing opportunities.